In SCLC models, AZD1775 was observed to trigger the activation of the STAT1-IFNγ pathway and increased the expression of PD-L1, and in immunocompetent SCLC mouse models, AZD1775 combined with PD-L1 blockade produced impressive tumor suppression [173]. Here, CD274 is linked to neoplasm.